Physician profile
Ryan K Pham
NPI 1407173230
$73,275.60
in general payments reported to CMS, 2019-2025
53 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,392 · 2020: $2,694 · 2021: $3,573 · 2022: $4,897 · 2023: $7,497 · 2024: $23K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $17K · Travel and Lodging: $2,434 · Consulting Fee: $1,800 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,250.00 |
| Food and Beverage | $16,941.91 |
| Travel and Lodging | $2,434.34 |
| Consulting Fee | $1,800.00 |
| Education | $292.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39,521.09 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $4,592.90 | 2019-2025 | |
| Amgen INC. | $3,053.90 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $2,344.87 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $2,325.61 | 2019-2025 | |
| Promius Pharma LLC | $2,121.38 | 2019 | |
| Galderma Laboratories, L.P. | $2,018.38 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Ucb, INC. | $1,904.89 | 2019-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $1,835.82 | 2019-2025 | |
| Janssen Biotech, INC. | $1,710.96 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Leo Pharma INC. | $1,662.76 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,434.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,409.91 | 2019-2025 | Dupixent, Libtayo |
| Celgene Corporation | $795.93 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $773.69 | 2019-2025 | Cabtreo, Siliq, Jublia |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.